Altasciences Supports Metsera in Clinical Trials for Obesity
Altasciences is committed to pushing the boundaries of medical science, particularly in developing innovative treatments for obesity. The integration of Metsera, Inc. into this vision represents a significant leap forward as they engage in early-stage clinical trials focused on obesity and related metabolic disorders.
Collaboration with Metsera
Metsera, a clinical stage biopharmaceutical company, is making strides in the field of obesity treatment through its nonclinical and early-stage clinical programs. Recently, Altasciences has provided substantial support to Metsera, including the completion of a critical Phase I/II trial for its drug candidate MET-097i. This innovative treatment, characterized as an ultra-long-acting injectable GLP-1 receptor agonist, has showcased promising results.
Encouraging Results from Clinical Trials
In recent updates, Metsera shared positive topline results from its clinical trial conducted at Altasciences' facilities. The trial demonstrated a notable 7.5% reduction in body weight from baseline at day 36, along with an impressive 380-hour half-life for MET-097i. These results mark a significant achievement in Metsera's efforts to develop effective obesity treatments and have paved the way for launching a randomized 16-week Phase II trial.
Comprehensive Support from Altasciences
Alongside its role in clinical trial management, Altasciences has offered Metsera a comprehensive Proactive Drug Development solution. This support spans various services including nonclinical, bioanalysis, CRO, and program management services designed for several additional therapeutic candidates. Notably, Altasciences has also completed nonclinical work for MET-233i, another promising treatment in their portfolio.
Addressing Global Health Challenges
The fight against obesity is critical, given that it affects millions globally and leads to serious health risks such as type 2 diabetes and heart disease. The innovative approaches being pursued through the clinical trials of MET-097i represent a beacon of hope for those battling this complex condition. As Altasciences and Metsera continue their partnership, they remain focused on developing effective solutions for obesity-related health challenges.
About Altasciences
Altasciences boasts more than 25 years of experience in integrated drug development solutions. The company partners with pharmaceutical and biotechnology businesses to provide tailored, flexible approaches to preclinical and clinical studies. Their comprehensive services cover preclinical safety testing, pharmacology studies, and proof of concept, while also offering bioanalysis and clinical monitoring. Altasciences is dedicated to helping sponsors accelerate the drug development process, ensuring that safer, more effective drugs reach those in need quickly.
Frequently Asked Questions
What is the focus of Altasciences' support for Metsera?
Altasciences supports Metsera mainly in their clinical trials for obesity treatments, including comprehensive drug development services.
What results were reported from the MET-097i trial?
The MET-097i trial indicated a 7.5% reduction in body weight from baseline after 36 days, showcasing the drug’s effectiveness.
How long has Altasciences been in operation?
Altasciences has over 25 years of experience in providing integrated drug development solutions.
Why is developing treatments for obesity important?
Obesity impacts millions of individuals globally and significantly increases the risk of serious health conditions, making effective treatments crucial.
What services does Altasciences offer?
Altasciences offers a range of services including preclinical and clinical studies, bioanalysis, data management, and program management tailored to specific sponsor needs.
